ReviewLung2020
ACE2: The Major Cell Entry Receptor for SARS-CoV-2.
Review in Lung, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05165992 (Nebulized Fentanyl for Respiratory Symptoms in Patients With COVID-19), which is not on this map. Cited by 298 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Nebulized Fentanyl for Respiratory Symptoms in Patients With COVID-19 (Ventanyl Trial)
Who cites it
298 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- New onset of type 1 and type 2 diabetes post-COVID-19 infection: a systematic review.Emerging microbes & infections · 2025Pooled it
- Pooled it
- A systematic review and meta-analysis of neuropathic pain associated with coronavirus disease 2019.European journal of pain (London, England) · 2023Pooled it
- Preeclampsia and severe acute respiratory syndrome coronavirus 2 infection: a systematic review.Journal of hypertension · 2022Pooled it
- Intravenous lanadelumab for the treatment of moderately ill COVID-19 patients.British journal of clinical pharmacology · 2026Trial
- Telmisartan reduces systemic inflammation and alters the renin-angiotensin system in mild COVID-19.Scientific reports · 2025Trial
- The landscape of plasma proteomic links to human organ imaging.Nature communications · 2026Article
- Heat-inactivated Bacillus spores attenuate poly I:C-induced lung inflammation and microbiome alterations through modulation of host immune responses.Scientific reports · 2026Article
- Persistent Olfactory Dysfunction Three Years After COVID-19: A Multicenter Observational Study.Pathogens (Basel, Switzerland) · 2026Observational
- Computational proteomics to enhance personalized treatment of COVID-19 and Long COVID.Clinical proteomics · 2026Review
- The lung-brain axis: elucidating the mechanisms of pulmonary-driven neurological disorders.Journal of neuroinflammation · 2026Review
- Myocardial and Vascular Involvement in COVID-19 and Post-Vaccination States: Understanding Injury Pathways and Clinical Implications.Life (Basel, Switzerland) · 2026Review
- RAAS antagonists dampen the SARS-CoV-2 infection in ex-vivo cultured human precision-cut lung slices.Respiratory research · 2026Article
- Extracellular vesicle-mediated delivery of CRISPR machinery silences androgen receptor in castration-resistant prostate cancer cells.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- Prediction of Functional Outcomes at Discharge Using Plasma Concentration of von Willebrand Factor Antigen at Admission in Hospitalized Patients with COVID-19.Annals of vascular diseases · 2026Article
- Integrative transcriptomic and single-cell analysis reveals a convergent cholangiocyte-associated host inflammatory program in biliary atresia and SARS-CoV-2-associated hepatobiliary injury.Frontiers in immunology · 2026Article
- Alpha- and Beta-Coronaviruses in Humans and Animals: Taxonomy, Reservoirs, Hosts, and Interspecies Transmission.Microorganisms · 2025Review
- Beyond the Spike Glycoprotein: Mutational Signatures in SARS-CoV-2 Structural Proteins.Infectious disease reports · 2025Article
- Biological Plausibility Between Long-COVID and Periodontal Disease Development or Progression.Biomedicines · 2025Review
- The impact of diabetes and obesity on the severity and mortality of SARS-CoV-2 infection.Journal of diabetes and metabolic disorders · 2025Review
238 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the unprecedented effort of the scientific community, the novel SARS-CoV-2 virus has infected more than 46 million people worldwide, killing over one million two hundred thousand. Understanding the mechanisms by which some individuals are more susceptible to SARS-CoV-2 infection and why a subgroup of them are prone to experience severe pneumonia, and death should lead to a better approach and more effective treatments for COVID-19. Here, we focus our attention on ACE2, a primary receptor of SARS-CoV-2. We will discuss its biology, tissue expression, and post-translational regulation that determine its potential to be employed by SARS-CoV-2 for cell entry. Particular attention will be given to how the ACE2 soluble form can have a great impact on disease progression and thus be used in a potential therapeutic strategy. Furthermore, we will discuss repercussions that SARS-CoV-2/ACE2 binding has on the renin-angiotensin system and beyond. Indeed, although mostly neglected, ACE2 can also act on [des-Arg 937]-bradykinin of the kinin-kallikrein system regulating coagulation and inflammation. Thorough comprehension of the role that ACE2 plays in different pathways will be the key to assess the impact that SARS-CoV-2/ACE2 binding has on organismal physiology and will help us to find better therapies and diagnostic tools.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.